Aethlon ’ s blood filtration device as broad countermeasure for infectious diseases

In the midst of a devastating global crisis 2 years ago, a Ugandan physician was infected with Ebola in Sierra Leone as he was treating patients. He was hospitalized at the Frankfurt University Hospital and 12 days later he was unconscious, suffering from multiple organ failure. By the time Aethlon Medical (NSDQ:AEMD) got permission to use its Hemopurifier device, the doctor required mechanical ventilation, continuous dialysis and vasopressor medications. After almost 7 hours of treatment with the single cartridge blood filtration device, the patient’s viral load dropped from 400,000 virus copies per milliliter of blood to 1,000 copies per milliliter. The doctor eventually made a full recovery. Aethlon CEO Jim Joyce told MassDevice.com that this story is a powerful example of what the device can do for viruses that do not have a known vaccine. He also pointed out that the “one bug, one drug” approach that scientists have used for years is not always the most efficient way to combat infectious disease outbreaks. “There’s just not enough candidates, realistically, to address these threats and many of the threats you don’t know what’s going to evolve next. As an example, Zika has been known since 1947, but no one could have predicted that it was going to unfold and become a threat at the pace that it did,” he said. “In reality, if you go to FDA’s own website, it would indicate that maybe 5 of every 5,000 drug cand...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Blood Management Food & Drug Administration (FDA) Research & Development Aethlon Medical Inc. MassDevice Q&A Source Type: news